Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo.

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the ...

Regeneron develops and commercializes Libtayo globally. About Immuneering Corporation Immuneering is a clinical-stage oncology company seeking to develop and commercialize more effective and ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

(RTTNews) - Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it ... in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small ...

but the company's strategic move to protect the franchise with a longer acting formulation has proved prescient. Moving forward, it is expected that sales growth momentum in DUPIXENT and LIBTAYO ...

more severe events occurred in 24% of those treated with Libtayo, compared to 14% with placebo. With the stock currently trading near its 52-week low, InvestingPro data suggests the company is ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...